ACADIA Pharmaceuticals Inc (ACAD) reports a 32% annual revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while expanding its pipeline and preparing for European market entry.

Talk about a heavy dose. While the bulk of news coverage is focused on GLP-1 drugs like Ozempic that cause weight loss, ...

Including additional features, such as genetic markers, comorbid medical conditions, and psychosocial factors, may enhance the model’s ability to predict treatment outcomes. Multimodal data ...